Past webinars

12. September 2023 | Friedreich Ataxia

20. June 2023 | Haematopoietic Stem Cell Transplantion in Leukodystrophies

13. June 2023 | Dissecting Fahr's disease

23. May 2023 | Frontotemporal dementia vs. primary psychiatric disorders

09. May | Non-pharmacological approaches to treatment in svPPA

14. March | FTD- in whom, when and how genetic testing should be applied

07. March | Towards precision medicine in NBIA

17. January | KMT2B-dystonia -organized by Juan Dario Ortigoza-Escobar (SJD)

6. July 2023 | Cardiac Involvement in Neuromuscular Diseases

4. May 2023 | Floppy child

9. March 2023 | Muscle hyperexcitability and cramps

06 December | Update in synuclein PET tracer development

22 November | Use of Biomarkers to monitor the presymptomatic phase of Genetic FTD: research advances for clinical trial readiness

15 November | Telerehabilitation in RND: an update

08 November | When is it appropriate to suspect a metabolic disorder in a child with chorea?

25 October | VPS13A and XK bulk lipid transfer diseases (formerly the now obsolete Levine-Critchley syndrome)

18 October | DBS in Dystonia – Targets, programming and therapeutic challenges

11 October | Krabbe disease – natural history and treatment option

27 September | Clinical and genetic predictors of subthalamic nucleus deep brain stimulation in Parkinson's disease

20 September | Tau-targeting Therapies: Where are we heading to?

13 September | Vanishing white matter

12 July | Importance of autopsies in leukodystrophies

05 July 2022 | Young onset Parkinson’s disease, what is the difference?

28 June 2022 | Magnetic resonance imaging in the diagnostic assessment of cerebellar ataxias

24 June 2022 | Caring HD: the experience of the French National Reference Centre

21 June 2022 | Biofluid biomarkers in atypical parkinsonism

12 April 2022 | Basal ganglia diseases in childhood

5 April 2022 | The logopenic variant of primary progressive aphasia (lvPPA): language, cognitive, neuroradiological issues

29 March 2022 | Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide

15 March 2022 | Measuring disease severity in chronic progressive myelopathy

8 March 2022 | Brain Development in Huntington’s Disease

15 February 2022 | New MDS criteria for clinical diagnosis of MSA

8 February 2022 | The overlap between the spectrum of frontotemporal dementias and atypical Parkinsonism

1 February 2022 | Learning by example: HD-JUNIOR a national registry for patients with juvenile onset Huntington's Disease

25 January 2022 | ASO RNA splice modulating therapies for genetic brain disorders

11 January 2022 | Anti-spastic therapies in Hereditary Spastic Paraplegia

29 September 2022 | Mitochondrial optic neuropathies

21 September 2022 | Mitochondrial Movement Disorders

1 September 2022 | Mitochondrial Epilepsy

21 April 2022 | Gene therapy, cancer and neuromuscular diseases

7 April 2022 | Duchenne Muscular Dystrophy Genetic Diagnosis

17 March 2022 | Primary mitochondrial myopathies

10 March 2022 | Muscle ultrasound, a biomarker tool for muscular dystrophies

24 February 202 | Targeted therapies for Leigh syndrome: systematic review and steps towards a "treatabolome"

3 February 2022 | An introduction into mitochondrial diseases in adulthood

27 January 2022 | Childhood onset Charcot-Marie-Tooth disease

7 December 2021 | Deep brain stimulation in children with acquired dystonia

23 November 2021 | Pure autonomic failure: really that pure?

9 November 2021 | Clinical Outcome Assessments in Ataxias

19 October 2021 | Oligonucleotide therapies: a new class of drugs that allow precise genetic targeting

12 October 2021 | Functional gait disorders: a sign-based approach

7 October 2021 | X-linked adrenoleukodystrophies – Update (paediatric focus)

5 October 2021 | Adult leukodystrophies - early symptoms of late onset leukodystrophies

28 September 2021 | Treatable dystonias & dystonia in inborn errors of metabolism

14 September 2021 | Genetic forms of Parkinson's disease

6 July 2021 | Speech as a biomarker in ataxia: What can it tell us and how should we use it?

15 June 2021 |Update Metachromatic Leukodystrophy

8 June 2021 | MRI pattern recognition in leukodystrophies

18 May 2021 | Benign hereditary choreas

11 May 2021 | Gene therapy in neuromuscular and mitochondrial disorders

4 May 2021 | Better Conversations - Communication Partner Training for language led dementias

20 April 2021 | Approach to the patient with non-HD chorea

13 April 2021 | MR Biomarkers in Spinocerebellar Ataxias

23 March 2021 | Challenges in Frontotemporal Dementia: clinical, genetic and pathological heterogeneity

9 March 2021 | Myoclonus dystonia

9 February 2021 | Rare Disease Natural History Studies: Experience from the GNAO1 Natural History study in a pre and postpandemic world

2 February 2021 | Genetic dystonia and treatment

26 January 2021 | Progressive Supranuclear Palsy – Update on Diagnostics, Biomarkers and Therapies

16 December 2021 | Palliative Care in Neuromuscular Disorders

18 November 2021 | Muscle and Statins

21 October 2021 | Rare Diseases’ therapies integration in diagnostic support tools through the Treatabolome platform

30 September 2021 | NGS results and CNV detection in Czech patients with neuromuscular disease

22 July 2021 | Summer school webinar: Overview of current state of the art of NMD management

8 July 2021 | Summer school webinar: Validation of MRI as a biomarker in clinical trials

10 June 2021 | Addressing disease heterogeneity in myotonic dystrophy. Towards personalized intervention

27 May 2021 | What’s new in the FSHD field?

20 May 2021 | Muscle and Ageing

1 April 2021 | Modeling Disease Progression in GNE Myopathy

11 March 2021 | Telemedicine in NMD: state of the art

18 February 2021 | Occurrence of both skeletal muscle and peripheral nerve involvement in genetic and acquired disorders

1 December 2020 | Functional movement disorders: a diagnostic guide

24 November 2020 | Development of Sara-home: a novel assessment tool for patients with ataxia

10 November 2020 | Rehabilitation in ataxia: current evidence and practice

3 November 2020 | Non-invasive stimulation for ataxias

20 October 2020 | Clinical practice recommendations for physical therapy for Huntington’s disease

13 October 2020 | Diagnostic algorithm for childhood onset chorea

6 October 2020 | Treatment of spasticity in HSP & leukodystrophies

1 October 2020 | Hereditary Spastic Paraplegia clinical disease course

29 September 2020 | Can we develop & implement evidence based rehabilitation for rare disorders?

15 September 2020 | A challenge in neurogenetics: Huntington disease in kids

10 September 2020 | How to assess and manage spastic gait in rare diseases?

8 September 2020 | Semantic variant of primary progressive aphasia

14 July 2020 | Gait rehabilitation in people with hereditary spastic paraplegia & Respiratory physiotherapy in parkinson's plus syndromes

9 July 2020 | Environmental modifiers in Hereditary Spastic Paraplegia

30 June 2020 | RCT on intrathecal baclofen in dystonia

18 June 2020 | Goal setting & outcome measures of interventions in paediatric rehabilitation

26 May 2020 | Primary progressive aphasia subtyping in clinical practice

12 May 2020 | Paroxysmal dyskinesias: update on clinical and genetic aspects

21 April 2020 | Hypomyelination

14 April 2020 | Recognizing atypical parkinsonism

6 April 2020 | Huntington's disease & COVID-19: a difficult combination

17 March 2020 | X-linked adrenoleukodystrophy

3 March 2020 | Ultrasound diagnostics for cervical dystonia

18 February 2020 | Mitochondrial disorder with chorea

4 February 2020 | Clinical evaluation of dystonia

28 January 2020 - | Introduction to Leukodystrophies

21 January 2020 | Immunue-mediated choreas

14 January 2020 | Inherited ataxias

10 December 2020 | Myasthenia Gravis

19 November 2020 | Congenital Myasthenia Syndrome - an update

29 October 2020 | Personalized care for patients with ALS: ALS Home monitoring & coaching

20 August 2020 | Painful neuropathies - from diagnosis to treatment

23 July 2020 | Introduction to MR Neurography

25 June 2020 | Paediatric muscle imaging

23 April 2020 | Exercise & NMD

17 December 2019 | Non-progressive congenital ataxia

3 December 2019 | Neuroacanthocytosis syndromes, a rare chorea

5 November 2019 | Clinical approach to cerebellar ataxia

21 November 2019 | Myotonic dystrophies

24 October 2019 | Diagnostic imaging in NMD: the basics

Solve RD webinar (v2) on basic analysis using the RD-Connect Genome-Phenome Analysis Platform (GPAP)

Solve RD webinar (v2) on advanced features of the RD-Connect Genome-Phenome Analysis Platform (GPAP)

WEBINAR 1| Cervical Dystonia Rehabilitation in Times of Difficulty in Having Access to Usual Therapy

WEBINAR 2| DYSTONIA AND MENTAL HEALTH Living well with dystonia

WEBINAR 3| NEUROMODULATION TREATMENT FOR DYSTONIAS Where do we stand?

WEBINAR 4| BOTULINUM TOXIN THERAPY OF DYSTONIA What is new?

WEBINAR 5| Neuromodulation for Dystonia in Childhood

WEBINAR 6| Care for dystonia in times of Covid-19

WEBINAR 7| Writer’s Cramp- Assessment and Rehabilitation Management

WEBINAR 8| DBS for dystonia: technical aspects, possibilities and limitations

WEBINAR 9| Current Dystonia Research Projects

18 January 2022: NGS analysis in ataxias: what it is and how it is done

14 December 2021: Magnetic resonance imaging in clinical care and research of ataxias

2023 | ERN-RND

2023 | ERN EURO-NMD

2022 | ERN-RND

2022 | ERN EURO-NMD

2021 | ERN-RND

2021 | ERN EURO-NMD

2020 | ERN-RND

2020 | ERN EURO-NMD

2019 | ERN-RND

2019 | ERN EURO-NMD

Past webinars from partner professional organisations

ERICA webinars

Solve-RD GPAP webinars 2021

Past webinars from ERN-RND member patient organisations

Eurordis

Dystonia Webinar Series

Past webinars from other organisations

Ataxia Global Young Investigator Initiative Webinar Series